title: Everolimus-induced pneumonitis after drug-eluting stent implantation: a case report.
abstract: Despite the wide use of everolimus as an antineoplastic coating agent for coronary stents to reduce the rate of restenosis, little is known about the health hazards of everolimus-eluting stents (EES). We describe a case of pneumonitis that developed 2 months after EES implantation for angina. Lung pathology demonstrated an organizing pneumonia pattern that responded to corticosteroid therapy. Although the efficacy of EES for ischemic heart disease is well established, EES carries a risk of pneumonitis.
authors.affiliation: Department of Respiratory Medicine, Toho University School of Medicine, Tokyo, Japan. susumu1029@gmail.com
authors.forename: Susumu
authors.initials: S
authors.lastname: Sakamoto
authors.forename: Naoshi
authors.initials: N
authors.lastname: Kikuchi
authors.forename: Atsuo
authors.initials: A
authors.lastname: Ichikawa
authors.forename: Go
authors.initials: G
authors.lastname: Sano
authors.forename: Keita
authors.initials: K
authors.lastname: Satoh
authors.forename: Keishi
authors.initials: K
authors.lastname: Sugino
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Isobe
authors.forename: Yujiro
authors.initials: Y
authors.lastname: Takai
authors.forename: Kazutoshi
authors.initials: K
authors.lastname: Shibuya
authors.forename: Sakae
authors.initials: S
authors.lastname: Homma
mesh_terms: D000368:Aged; D000787:Angina Pectoris / Q000000981:diagnostic imaging / Q000628:therapy; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects* / Q000379:methods; D023903:Coronary Restenosis / Q000000981:diagnostic imaging / Q000628:therapy*; D023921:Coronary Stenosis / Q000000981:diagnostic imaging / Q000628:therapy; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D000068338:Everolimus; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D017239:Paclitaxel / Q000627:therapeutic use; D011014:Pneumonia / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology*; D011239:Prednisolone / Q000627:therapeutic use; D013902:Radiography, Thoracic; D019233:Retreatment; D018570:Risk Assessment; D020123:Sirolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000068338:Everolimus; D011239:Prednisolone; D017239:Paclitaxel; D020123:Sirolimus